A new technology of using small molecules to remove pathological proteins

Recently, a research team led by Craig crews, a molecular cell and developmental biology scientist from Yale University, including scientists from GlaxoSmithKline and arvinas, has developed a method to block pathogenic proteins efficiently with small molecules, which can not only inhibit the function of target proteins, but also completely eliminate them This small molecule drug is called proteolysis targeted chimeras (protacs) It has the affinity to target protein and E3 ubiquitin ligase at the same time This E3 ubiquitin ligase will start a powerful ubiquitin hydrolysis process after binding with the target protein, so that the target protein can be degraded by using the human body's own protein degradation The mechanism removes any target pathogenic proteins Because the small molecule drug can be repeatedly combined with other target proteins after the target protein is labeled and degraded, which means that it can work at a low dose Therefore, the drug can not only target many proteins that are difficult to inhibit with existing drugs, but also safely achieve this goal.